cresence AS

Bioasis Acquires Phase 2 Ready Rare Orphan EGF Assets

Cresence is proud to announce that it has sold its assets and IP rights to Bioasis Inc, a USA biotech company listed on the Canadian stock market.
A move which will accelerate the development of Cresence products towards the market- for details.


Please refer to the Joint Bioasis Cresence Press Release.

READ THE PRESS RELEASE HERE

Leave a Comment